IP Library Granted Patent US 10,696,746
Granted Patent B2
US 10,696,746 · App. 15/925,494 · Granted Jun 30, 2020

Antigen binding proteins that bind CCR2

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,696,746
App. No.
15/925,494
Granted
Jun 30, 2020
Kind
B2
Abstract

There is disclosed compositions and methods relating to or derived from anti-CCR2 antibodies. More specifically, there is disclosed fully human antibodies that bind CCR2, CCR2-binding fragments and derivatives of such antibodies, and CCR2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CCR2 related disorders or conditions.

Claims (5)

1. A recombinant fully human antibody of an IgG class that binds to a CC-Chemokine Receptor 2 (CCR2) epitope wherein the antibody comprises the heavy chain variable domain sequence of SEQ ID NO:5 and that comprises the light chain variable domain sequence of SEQ ID NO:2.

2. A Fab fully human antibody fragment having a variable domain region from a heavy chain and a variable domain region from a light chain, wherein the heavy chain variable domain sequence is the amino acid sequence of SEQ ID NO:5 and the light chain variable domain sequence is the amino acid sequence of SEQ ID NO:2.

3. A single chain human antibody having a variable domain region from a heavy chain and a variable domain region from a light chain and a peptide linker connecting the heavy chain and light chain variable domain regions, wherein the heavy chain variable domain sequence is the amino acid sequence of SEQ ID NO:5 and the light chain variable domain sequence is the amino acid sequence of SEQ ID NO:2.

4. The recombinant fully human antibody of claim 1 , which is of an IgG1 or IgG4 class.

5. A pharmaceutical composition comprising the recombinant fully human antibody of claim 1 , and a pharmaceutically acceptable excipient.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2024
From: SORRENTO THERAPEUTICS, INC.
To: VIVASOR, INC.
Reel/Frame 067529/0019 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 21, 2023
From: SCILEX HOLDING COMPANY
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 065017/0844 →
RELEASE OF SECURITY INTEREST Recorded Aug 11, 2023
From: JMB CAPITAL PARTNERS LENDING, LLC
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 064571/0848 →
SECURITY INTEREST Recorded Jul 31, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: SCILEX HOLDING COMPANY
Reel/Frame 064441/0575 →
SECURITY INTEREST Recorded Apr 6, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 063283/0063 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2020
From: OAKTREE FUND ADMINISTRATION, LLC
To: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 053368/0577 →
SECURITY INTEREST Recorded Nov 7, 2018
From: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 047446/0335 →